stocks logo

ACRS

Aclaris Therapeutics Inc
$
1.680
-0.02(-1.176%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.760
Open
1.720
VWAP
--
Vol
841.31K
Mkt Cap
181.91M
Low
1.640
Amount
--
EV/EBITDA(TTM)
--
Total Shares
71.26M
EV
78.76M
EV/OCF(TTM)
--
P/S(TTM)
8.62
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.39M
-84.9%
-0.143
-85.81%
1.36M
-68.69%
-0.138
+25.75%
1.29M
-53.47%
-0.128
-14.45%
Estimates Revision
The market is revising Downward the revenue expectations for Aclaris Therapeutics, Inc. (ACRS) for FY2025, with the revenue forecasts being adjusted by -53.09% over the past three months. During the same period, the stock price has changed by 26.32%.
Revenue Estimates for FY2025
Revise Downward
down Image
-53.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-10.76%
In Past 3 Month
Stock Price
Go Up
up Image
+26.32%
In Past 3 Month
6 Analyst Rating
up Image
425.60% Upside
Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 8.83 USD with a low forecast of 6.00 USD and a high forecast of 16.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
up Image
425.60% Upside
Current: 1.680
sliders
Low
6.00
Averages
8.83
High
16.00
Piper Sandler
Biren Amin
Overweight
initiated
$6
2025-07-09
Reason
Piper Sandler analyst Biren Amin assumed coverage of Aclaris Therapeutics with an Overweight rating and $6 price target. The shares are currently trading below the company's cash position with three data readouts over the next 12-15 months, the analyst tells investors in a research note. The firm believes each readout offers "meaningful upside" to Aclaris shares. Piper believes the company's lead program, bosakitug, has demonstrated proof of efficacy activity in a small Phase 2a study in moderate to severe atopic dermatitis.
Wedbush
NULL -> Outperform
initiated
$8
2025-05-28
Reason
Wedbush initiated coverage of Aclaris Therapeutics with an Outperform rating and $8 price target.
Wedbush
Outperform
initiated
$8
2025-05-28
Reason
H.C. Wainwright
Raghuram Selvaraju
Buy
downgrade
$20 -> $16
2025-05-14
Reason
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Aclaris Therapeutics to $16 from $20 and keeps a Buy rating on the shares following the Q1 report.
Scotiabank
Louise Chen
Outperform
downgrade
$15 -> $9
2025-05-09
Reason
Scotiabank analyst Louise Chen lowered the firm's price target on Aclaris Therapeutics to $9 from $15 and keeps an Outperform rating on the shares. The firm is lowering its price target on the stock due to lower sales for bosakitug, the analyst tells investors. The firm, however, continues to believe pipeline advancements and commercialization, as well as potential partnerships, will drive upwards earnings revisions.
Cantor Fitzgerald
Prakhar Agrawal
Buy
Reiterates
n/a
2025-03-18
Reason

Valuation Metrics

The current forward P/E ratio for Aclaris Therapeutics Inc (ACRS.O) is -3.17, compared to its 5-year average forward P/E of -6.46. For a more detailed relative valuation and DCF analysis to assess Aclaris Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.46
Current PE
-3.17
Overvalued PE
-1.90
Undervalued PE
-11.02

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.70
Undervalued EV/EBITDA
-3.83

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
71.73
Current PS
32.84
Overvalued PS
134.47
Undervalued PS
8.98

Financials

Annual
Quarterly
FY2025Q1
YoY :
-39.32%
1.46M
Total Revenue
FY2025Q1
YoY :
+10.25%
-17.78M
Operating Profit
FY2025Q1
YoY :
-10.96%
-15.09M
Net Income after Tax
FY2025Q1
YoY :
-50.00%
-0.12
EPS - Diluted
FY2025Q1
YoY :
-33.49%
-13.93M
Free Cash Flow
FY2025Q1
YoY :
-118.01%
-4.19
Gross Profit Margin - %
FY2025Q1
YoY :
+16.40%
-275.58
FCF Margin - %
FY2025Q1
YoY :
+46.76%
-1.04K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
15.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ACRS News & Events

Events Timeline

2025-07-28 (ET)
2025-07-28
08:53:28
Aclaris Therapeutics CSO Joe Monahan to retire, Roland Kolbeck to succeed
select
2025-06-23 (ET)
2025-06-23
07:13:19
Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
select
2025-06-02 (ET)
2025-06-02
07:09:42
Aclaris Therapeutics initiates Phase 2 trial of bosakitug
select
Sign Up For More Events

News

4.5
06-30Newsfilter
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
1.0
06-26Newsfilter
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
4.0
06-25Benzinga
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
Sign Up For More News

FAQ

arrow icon

What is Aclaris Therapeutics Inc (ACRS) stock price today?

The current price of ACRS is 1.68 USD — it has decreased -1.18 % in the last trading day.

arrow icon

What is Aclaris Therapeutics Inc (ACRS)'s business?

arrow icon

What is the price predicton of ACRS Stock?

arrow icon

What is Aclaris Therapeutics Inc (ACRS)'s revenue for the last quarter?

arrow icon

What is Aclaris Therapeutics Inc (ACRS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Aclaris Therapeutics Inc (ACRS)'s fundamentals?

arrow icon

How many employees does Aclaris Therapeutics Inc (ACRS). have?

arrow icon

What is Aclaris Therapeutics Inc (ACRS) market cap?